Mortality in intracoronary versus intravenous abciximab - Authors' reply

Holger Thiele; Ingo Eitel; Oana Brosteanu; Steff En Desch; Gerhard Schuler

doi:10.1016/S0140-6736(12)61121-0

Mortality in intracoronary versus intravenous abciximab - Authors' reply

Holger Thiele^*, Ingo Eitel, Oana Brosteanu, Steff En Desch, Gerhard Schuler

^*Korrespondierende/r Autor/-in für diese Arbeit

Medizinische Klinik II

Universität Leipzig

Originalsprache	Englisch
Zeitschrift	The Lancet
Jahrgang	380
Ausgabenummer	9836
Seiten (von - bis)	26
Seitenumfang	1
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(12)61121-0
Publikationsstatus	Veröffentlicht - 07.2012

Fördermittel

HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Zentren: Universitäres Herzzentrum Lübeck (UHZL)

DFG-Fachsystematik

2.22-12 Kardiologie, Angiologie

Dokumente

10.1016/S0140-6736(12)61121-0

Weitere Links

Link to publication in Scopus

Zitieren

@article{bbf049dc01ca4f1d86d24d1db887880c,

title = "Mortality in intracoronary versus intravenous abciximab - Authors' reply",

author = "Holger Thiele and Ingo Eitel and Oana Brosteanu and \{En Desch\}, Steff and Gerhard Schuler",

note = "Funding Information: HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.",

year = "2012",

month = jul,

doi = "10.1016/S0140-6736(12)61121-0",

language = "English",

volume = "380",

pages = "26",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9836",

}

TY - JOUR

T1 - Mortality in intracoronary versus intravenous abciximab - Authors' reply

AU - Thiele, Holger

AU - Eitel, Ingo

AU - Brosteanu, Oana

AU - En Desch, Steff

AU - Schuler, Gerhard

N1 - Funding Information: HT has received an unrestricted grant from Lilly, and speaker's fees from Lilly, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and the Medicines Company. All other authors declare that they have no conflicts of interest.

PY - 2012/7

Y1 - 2012/7

UR - https://www.scopus.com/pages/publications/84863431198

U2 - 10.1016/S0140-6736(12)61121-0

DO - 10.1016/S0140-6736(12)61121-0

M3 - Letters

AN - SCOPUS:84863431198

SN - 0140-6736

VL - 380

SP - 26

JO - The Lancet

JF - The Lancet

IS - 9836

ER -